First Patient Dosed in OYE Therapeutics IV Caffeine 505(b)(2) Bridging Study
Key points:
- First patient dosed in a 505(b)(2) bridging study of OYE-101
- OYE-101 is an intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation
- Study will generate human data to support a future 505(b)(2) regulatory submission
- Program targets unmet needs in perioperative recovery and acute-care respiratory support
The study is designed to generate human data supporting a future 505(b)(2) new drug application, a regulatory pathway that allows developers to leverage existing data on previously approved drugs while conducting targeted studies to bridge to a new formulation or use.
OYE-101 is an intravenous formulation of caffeine being developed to accelerate recovery from general anesthesia and deep sedation. According to the company, the therapy is intended to address gaps in perioperative and acute-care medicine, where delayed emergence and residual sedation can prolong recovery times and contribute to complications.
The bridging study represents an early clinical step aimed at establishing pharmacologic effects in humans and supporting the program’s regulatory strategy. The company described the study as part of a broader effort to demonstrate that its formulation can enable faster and more predictable recovery from anesthesia while maintaining patient safety.
General anesthesia and deep sedation are widely used across surgical and procedural settings, with millions of cases performed annually. However, no FDA-approved therapies are currently indicated to actively promote emergence from anesthesia, according to the company, highlighting the unmet need the program is intended to address.
Beyond perioperative use, OYE-101 is also being developed for potential applications in emergency and acute-care settings, including as a respiratory stimulant in situations such as opioid-induced respiratory depression.
The company framed the first-patient-first-dose milestone as a key step in advancing its clinical development strategy, with data from the bridging study expected to inform subsequent trials and support regulatory submissions.
OYE Therapeutics, a clinical-stage biopharmaceutical company based in Indiana, is focused on developing intravenous caffeine-based therapies aimed at improving recovery and respiratory outcomes in surgical, emergency, and critical care environments.